CEPIUpdates from CEPI

100 Days to Outrace the Next Pandemic

What will it take to create safe and effective vaccines in 100 days? Watch this session from the World Economic Forum to learn how CEPI is accelerating the development of vaccines and enabling equitable access during outbreaks.
Watch the video

CEPI and Institut Pasteur de Dakar announce 10-year partnership

With an investment representing $50 million over 10 years, this partnership between CEPI and Institut Pasteur de Dakar will boost manufacturing of affordable vaccines for the Global South.
Read more

CEPI invests to advance development of Vaxxas’ needle-free vaccine-patch delivery technology

CEPI and Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology. This project aims to end the need for frozen storage and improve vaccine development in response to outbreak threats.
Read more

CEPI to partner with Belgium universities to enhance global pandemic preparedness

CEPI has entered into strategic partnerships with the Belgian Universities KU Leuven and the University of Antwerp to collaborate in areas that will contribute to improved global pandemic preparedness.
Read more

Real-world effectiveness of COVID-19 vaccines

In this article Mario Christodoulou, CEPI’s Senior Communications and Advocacy Manager,  discusses why real-world vaccine-effectiveness studies are essential to inform vaccine roll-out strategies and how CEPI is supporting such studies.
Read more

CEPI announces partnership with Tiba Biotech

CEPI and Tiba Biotech, a preclinical biopharmaceutical company, have announced a new partnership agreement to evaluate Tiba Biotech’s next-generation RNA vaccine platform technology to respond to ‘Disease X’.
Read more

Stabilised mRNA vaccine tech aims to end need for frozen storage and improve access

CEPI and Netherlands-based 20Med have partnership to advance development of 20Med’s bioresponsive polymeric nanoparticle platform for mRNA stabilisation and delivery.
Read more

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.